特朗普要求制药巨头降低美国药价 诺和诺德跌超6% 智通财经8月1日电，诺和诺德跌超6%，阿斯利康跌超3%。美国总统特朗普周四表示，他已要求全球主 要制药公司在未来60天内采取措施降低美国药品价格。 ...

Denmark's farmer giant Novon Nordisk has a problem. Copycats. About 1 million patients in the US are using cheaper versions of its blockbuster weight loss and diabetes drugs.And it's hurting Noville's bottom line. The company has lost about 2/3 of its value in the past year, wiping out hundreds of billions of dollars. It's now slashed its earnings outlook for the second time this year, sending shares plunging 23% in a day.Norville's imitation problem stems from a failure to meet the demand for its drugs whi ...

Core Viewpoint - HSBC has downgraded Novo Nordisk's stock rating from "Buy" to "Hold" due to the company's warning regarding its business outlook for 2025, indicating a significant reduction in growth expectations compared to previous market forecasts [1][2] Group 1: Company Performance - Novo Nordisk's management has indicated that its revenue growth rate may stabilize at a low single-digit percentage level in 2025, which is a notable decline from earlier optimistic market predictions [1] - The company has revised its full-year sales growth forecast from 13%-21% down to 8%-14%, and its operating profit growth forecast from 16%-24% down to 10%-16% [2] Group 2: Market Challenges - The GLP-1 drug market, which is a core driver of Novo Nordisk's sales, is facing multiple challenges, including illegal sales by U.S. compounders that are squeezing the company's market space [1] - Internal management changes have led to delays in execution efficiency, further undermining market confidence in the company's short-term profit outlook [1] Group 3: Valuation Adjustments - HSBC has lowered its long-term peak sales expectations for Novo Nordisk's main products, resulting in a 5% and 16% reduction in earnings forecasts for 2025 and 2026, respectively [1] - The target price for Novo Nordisk's stock has been significantly reduced from 680 Danish Krone to 360 Danish Krone, representing a 47% decrease [1] Group 4: Leadership Changes - The current CEO, Lars Fruergaard Jørgensen, is stepping down due to pressure from stock performance, with Maziar Mike Doustdar, who has over 30 years of experience in international operations, taking over [2] - This leadership change has sparked mixed reactions among investors, with some supporting the new CEO's experience while others believe the company needs a leader with U.S. market experience to face competition from rivals like Eli Lilly [2]

Core Viewpoint - Novo Nordisk significantly lowered its full-year financial outlook and appointed Maziar Mike Doustdar as the new CEO, succeeding the current CEO [2] Financial Outlook - The company revised its full-year sales growth forecast from 13%-21% to 8%-14% [2] - The operating profit growth forecast was adjusted from 16%-24% to 10%-16% [2] - Following the announcement, the company's stock price dropped by 28%, resulting in a market value loss of approximately $93 billion [2] Reasons for Downgrade - The primary reason for the lowered performance expectations is the poor sales of "Wegovy" (weight loss version of semaglutide), attributed to slower-than-expected expansion in the U.S. obesity market and significant illegal circulation of generic GLP-1 drugs [2] - Additionally, "Ozempic" (diabetes version of semaglutide) is experiencing slowed growth due to increased competition in the U.S. GLP-1 diabetes drug market, leading patients to switch to competing products [2] - International market performance has also fallen short of expectations, with Wegovy's penetration in certain international markets being below company targets [2] Industry Perspective - Industry observers note that while the global obesity issue presents significant opportunities for the weight loss drug market, companies face intensified competition from multi-target drugs, a more complex payment environment, and stricter regulatory requirements [2] - There is an increasing sensitivity in the capital markets regarding the risks associated with pharmaceutical companies' reliance on single products [2]

当地时间7月31日，美股高开低走，三大指数集体收跌，截至收盘，道琼斯指数跌0.74%，标普500指数跌0.37%，纳斯达克指数跌0.03%。 微软开盘市值一度冲上4万亿美元，截至收盘股价上涨3.95%，总市值3.97万亿美元。 消息面上，美国总统特朗普向17家制药公司发出通牒，要求其在60天内采取措施大幅削减美国药品价格，美股制药股全线下挫。此外，特朗普在其社交平 台上表示，美国与墨西哥的关税协议将延长90天。特朗普还再度批评鲍威尔，称他"又犯了错"，根本不配担任美联储主席。 当地时间周四，美股热门科技股涨跌不一，Meta涨超11%，总市值达1.94万亿美元，距离2万亿美元大关仅一步之遥。这得益于公司炸裂的业绩，二季度 Meta受AI驱动，营收达475.2亿美元，同比增长22%，远超市场预期的448亿美元，公司净利润达183.4亿美元，同比增长36%，同样超出预期。 微软股价上涨3.95%，业绩同样受益于AI的驱动。2025财年第四财季，微软营收为764.4亿美元，同比增长18%，其中智能云业务（含Azure）营收达298.8 亿美元，同比增长26%，公司净利润达272亿美元，同比增长24%。 苹果股价下跌0 ...

NEW YORK, July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. [Click here for information about joining the class action] CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 On July 29, 2025, Novo Nordisk significantly lowered its sales outlook for 2025, citing the impact of ...

Group 1 - President Trump has sent letters to 17 major pharmaceutical companies, demanding specific actions to lower drug prices in the U.S. within 60 days, or he will use "all available means" to protect American families from "price gouging" [1][2] - The companies that received the letters include Pfizer, Novo Nordisk, Johnson & Johnson, and others, with a focus on commitments such as providing "most favored nation" pricing for Medicaid patients and direct sales to consumers [1][2] - Trump highlighted that U.S. drug prices are significantly higher than those in other developed countries, with average prescription drug prices being 2 to 3 times higher, and some drugs up to 10 times more expensive [2] Group 2 - Following the announcement, stock prices of several pharmaceutical companies dropped, with Sanofi falling over 8%, and others like Bristol-Myers Squibb and Novo Nordisk declining nearly 5% [2] - The Pharmaceutical Research and Manufacturers of America criticized the introduction of "foreign price controls," arguing it would undermine U.S. innovation and harm patients and workers [3] - Companies like Pfizer and Novartis stated they are working on solutions to make medications more affordable for American patients, with AstraZeneca considering price reductions and direct sales models [3]

半导体设备与材料、减肥药概念股跌幅居前，诺和诺德跌近6%，科磊跌近5%，阿斯麦跌超3%，礼来、 辉瑞跌超2%。设计软件巨头Figma上市首日上涨256%。 格隆汇8月1日｜美股三大指数集体收跌，道指跌0.74%，纳指跌0.03%，标普500指数跌0.37%，热门科 技股涨跌不一，Meta涨超11%，微软涨3.95%，亚马逊涨1.70%，特斯拉跌3.38%，谷歌A跌2.36%，英伟 达跌0.78%，苹果跌0.71%，礼来制药跌2.63%，AMD跌1.78%，伯克希尔哈撒韦B类股跌0.87%。 纳斯达克中国金龙指数收涨0.66%，热门中概股多数上涨，蔚来涨近8%，金山云涨超5%，阿里巴巴、 哔哩哔哩、百度涨超2%，理想汽车跌超1%，名创优品跌超4%。 ...

Core Viewpoint - The MSCI Nordic Countries Index has declined by 1.4%, closing at 335.73 points, marking the lowest close since April 29 [1] Company Performance - The healthcare sector in the Nordic region led the decline, with Novo Nordisk experiencing a drop of 3.2%, contributing significantly to the overall market downturn [1] - DSV A/S saw a notable decline of 4.8%, making it the worst performer among the index constituents [1]

Core Viewpoint - Deutsche Bank indicates that Novo Nordisk's current valuation reflects that of a mature pharmaceutical company lacking growth momentum, raising questions about whether the lowered guidance is due to a conservative management approach or a genuine deterioration in business prospects [1][3]. Group 1: Performance Guidance - Novo Nordisk has lowered its 2025 fiscal year sales growth guidance to a range of 8-14% and EBIT growth to 10-16%, which is a significant reduction from previous expectations [6]. - To meet the new lower limit of 8% sales growth, Novo Nordisk would need to achieve nearly zero growth in the second half of the year, which is challenging given the current performance of Wegovy and Ozempic [6]. - Deutsche Bank notes that the upper end of the revised guidance aligns closely with their prior expectations, suggesting that the market is currently pricing Novo Nordisk as a company that has lost its growth momentum [6]. Group 2: Market Dynamics and Competition - The ongoing competition from compounded generic drugs continues to impact Novo Nordisk, with approximately 1 million patients in the U.S. still using compounded medications [4]. - Despite an increase in 503A supply to offset the decline in 503B, the overall competitive landscape has not improved, raising concerns about Novo Nordisk's ability to reduce the influx of compounded drugs into the market [4]. - Analysts believe that Novo Nordisk should expand its market for semaglutide-based drugs in the second half of the year, but failure to do so may indicate flaws in the market's total addressable market (TAM) assumptions [5]. Group 3: Strategic Focus and Market Potential - The new CEO of Novo Nordisk has stated that the company will prioritize innovation investments and commercial execution, with cash prescription business share increasing from 4% at the beginning of the year to 12% [5]. - In the obesity market, it is confirmed that out of 100 million obese individuals, 55 million have employer-sponsored insurance coverage for Wegovy, indicating a significant market opportunity [5]. - Wegovy's prescription volume has reached approximately 275,000, with new prescription share rising to over 40%, suggesting a positive trend in market uptake [5].